Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Annexon, Inc. - common stock (NQ:ANNX)

2.880 -0.140 (-4.64%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Annexon, Inc. - common stock

< Previous 1 2 3 4 5 6 7 Next >
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 26, 2023
 
Via Benzinga
Crude Oil Drops Sharply; Best Buy Earnings Top Expectations
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite gaining more than 200 oints on Thursday. The Dow traded down 0.02% to 32,793.29 while the NASDAQ rose 1.78% to 12,706.89.... 
Via Benzinga
Analyst Expectations for Annexon's Future
 
Via Benzinga
Why Annexon (ANNX) Stock Is Getting Hammered
Annexon Inc (NASDAQ: ANNX) shares are trading lower by some 57.16% to $2.96 Thursday morning. 
Via Benzinga
Annexon's Eye Disease Drug Reports Mixed Trial Results, Will Focus On Planned Late-Stage Study
 
Via Benzinga
Analyst Ratings for Annexon
 
Via Benzinga
The Latest Analyst Ratings for Annexon
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
Why Dollar Tree Shares Are Trading Lower By 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers Beamr Imaging Ltd. (NASDAQ: BMR) shares climbed 211.6% to $6.86 after NVIDIA announced the release of NVENC Video Codec SDK 12.1 showcasing the integration with Beamr CABR. 
Via Benzinga
Nasdaq Surges 1.5%; NVIDIA Shares Jump Following Strong Q1 Results
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite gaining over 1.5% on Thursday. The Dow traded down 0.20% to 32,733.60 while the NASDAQ rose 1.53% to 12,674.85. The S&P 500,... 
Via Benzinga
Why Shares of Annexon Are Plummeting Thursday
Mixed trial results on a geographic atrophy eye drug led investors to sell the biotech stock. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For May 25, 2023
 
Via Benzinga
Dow Drops 100 Points; US GDP Tops Estimates
U.S. stocks traded mixed this morning, with the Nasdaq Composite gaining over 1% on Thursday. Following the market opening Thursday, the Dow traded down 0.34% to 32,687.15 while the NASDAQ rose 1.36%... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
We're starting off Thursday with a breakdown of the biggest pre-market stock movers traders need to know about this morning! 
Via InvestorPlace
Annexon Topline Data from ARCHER Phase 2 Trial of ANX007 in Geographic Atrophy Demonstrated Statistically Significant, Dose-Dependent Preservation of Visual Function
From Annexon Biosciences
Via GlobeNewswire
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire
Annexon Reports First Quarter 2023 Financial Results and Highlights Recent Pipeline Progress
From Annexon Biosciences
Via GlobeNewswire
Annexon Biosciences to Participate in the 22nd Annual Needham Virtual Healthcare Conference
From Annexon Biosciences
Via GlobeNewswire
Annexon Reports Fourth Quarter and Year-End 2022 Financial Results and Reiterates Anticipated Milestones
From Annexon Biosciences
Via GlobeNewswire
Annexon Biosciences to Participate in the 43rd Annual Cowen Healthcare Conference
From Annexon Biosciences
Via GlobeNewswire
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire
Annexon Highlights Strategic Focus to Advance Four Flagship Complement Programs through Late-Stage Development and Progress Across Three Therapeutic Franchises
From Annexon Biosciences
Via GlobeNewswire
Annexon Appoints Industry Veteran, Dr. Rick Artis, as Chief Scientific Officer to Support the Advancement and Expansion of Complement-focused Portfolio
From Annexon Biosciences
Via GlobeNewswire
Annexon to Present at 41st Annual J.P. Morgan Healthcare Conference
From Annexon Biosciences
Via GlobeNewswire
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire
Annexon: Q3 Earnings Insights
Annexon (NASDAQ:ANNX) reported its Q3 earnings results on Thursday, November 3, 2022 at 06:30 AM. Here's what investors need to know about the announcement. Earnings Annexon beat estimated earnings by... 
Via Benzinga
Annexon Reports Third Quarter 2022 Financial Results and Plans to Provide Updates on Complement Therapeutic Portfolio in January 2023
From Annexon Biosciences
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.